Cell therapy (Stem-cell derived) · developed by Mesoblast
Rexlemestrocel-L is an allogeneic cell therapy made of human bone marrow-derived mesenchymal precursor cells, isolated with anti-STRO-3 antibodies, expanded ex vivo and cryopreserved. It is studied in degenerative disc disease and chronic heart failure.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06325566 | Phase 3 | Degenerative Disc Disease | Active not recruiting | MESO |
| NCT02032004 | Phase 3 | Chronic Heart Failure | Completed | MESO |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Degenerative Disc DiseaseChronic Heart Failure
Updated Oct 18, 2026. Something wrong or missing? Report it on the MESO page.
See MESO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
MESO catalysts and pipeline →